Survodutide — wholesale 10-vial kits

Research context

Survodutide is a glucagon / GLP-1 receptor dual agonist from the oxyntomodulin-inspired class: one acylated peptide that activates both the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R). It was discovered at Zealand Pharma and licensed to Boehringer Ingelheim, which is responsible for its global development under the code BI 456906. Much of the published work on it concerns the liver.

Molecular design and preclinical pharmacology. Boehringer Ingelheim's discovery paper (Zimmermann et al., Molecular Metabolism, 2022) describes survodutide as a potent acylated peptide carrying a C18 fatty acid as its half-life-extending element; the full map of its non-standard residues is in the FDA GSRS record (UNII 2ALA66NS64). Engagement of each receptor was demonstrated with separate read-outs: glucose tolerance, food intake and gastric-emptying tests for the GLP-1 receptor, and hepatic nicotinamide N-methyltransferase (NNMT) mRNA expression plus circulating amino acids and FGF-21 for the glucagon receptor. GLP-1 receptor knockout mice, transgenic reporter mice and an ex-vivo bioactivity assay were used to confirm the dual activity. In mice, its body-weight reduction exceeded that of maximally effective semaglutide, through increased energy expenditure as well as reduced food intake.

In the laboratory, survodutide is used to study how glucagon-receptor activation alters hepatic fat handling, fibrosis markers and energy expenditure in animal models, and how those effects interact with GLP-1 receptor signaling. The glucagon-receptor biomarkers from the discovery work (hepatic NNMT expression, FGF-21 and plasma amino acids) are useful target-engagement read-outs for any GCGR agonist, and the knockout and reporter-mouse designs are a template for separating the two arms of a dual agonist. It is commonly compared with mazdutide and with the triple agonist retatrutide in receptor-potency and hepatic-metabolism studies.

U.S. regulatory status: survodutide is investigational and is not approved by the FDA or any other regulator. Its Phase 2 study in MASH with fibrosis was published in the New England Journal of Medicine in 2024, and reports from the Phase 3 SYNCHRONIZE program appeared in Nature Medicine and the New England Journal of Medicine in 2026. The survodutide sold by WholesalePeptide.us is a research reference compound supplied only for in-vitro, analytical and preclinical laboratory research.

For comparison studies across the GLP-1 / glucagon class, the useful quality data are the same for every compound: an RP-HPLC trace showing related-substance peaks, an LC-MS mass that matches the lipidated structure, and net peptide content so concentrations can be corrected. Every survodutide lot we ship has a COA with all three, published before the lot ships, and the compound can be ordered in the same kit tier as mazdutide and retatrutide.

Survodutide is lyophilized and supplied as a single compound at a single strength per kit. Because its GSRS entry does not spell out every non-standard residue in a plain one-letter sequence, the measured LC-MS mass on the lot COA is the practical identity check, and incomplete acylation is the related substance most worth looking for on the chromatogram.

Research areas

• Glucagon / GLP-1 receptor dual agonism
• Hepatic steatosis and fibrosis models
• Energy-expenditure studies in rodents
• Glucagon-receptor target-engagement biomarkers (NNMT, FGF-21, amino acids)
• Comparative incretin pharmacology

U.S. regulatory status of the compound (as an active ingredient): Investigational peptide, not approved by the FDA or any regulator. The material sold here is a research reference chemical, not a drug product.

Handling and storage

• Store lyophilized vials at −20 °C, sealed, protected from light and moisture.
• Let the vial reach room temperature before opening to limit condensation on the powder.
• Reconstitute in a sterile buffer appropriate to the assay, following your lab's SOP.
• Aliquot reconstituted material and freeze once; avoid repeated freeze–thaw.